Shopping Cart
- Remove All
- Your shopping cart is currently empty
Refanezumab (GSK249320) is an IgG1 humanized monoclonal antibody that crosses the blood-brain barrier (BBB) and targets myelin-associated glycoprotein (MAG) for the study of neurological and cardiovascular diseases.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $450 | In Stock | |
5 mg | $1,400 | In Stock | |
10 mg | $2,220 | In Stock | |
25 mg | $4,210 | In Stock |
Description | Refanezumab (GSK249320) is an IgG1 humanized monoclonal antibody that crosses the blood-brain barrier (BBB) and targets myelin-associated glycoprotein (MAG) for the study of neurological and cardiovascular diseases. |
In vivo | Male Sprague Dawley rats were administered 10 mg/kg Refanezumab intravenously starting 24 hours after stroke onset and repeated weekly for a total of 6 doses. The results showed that this treatment resulted in significant improvements in neurologic scores and step tests. Refanezumab was able to penetrate the damaged area and had some positive impact on functional recovery within 24 hours of stroke. [1] |
Alias | GSK249320, GSK 249320 |
Molecular Weight | 145.5 kDa |
Cas No. | 1233953-61-1 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.